SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY.

MicroCloud Hologram Inc

MicroCloud Hologram ($HOLO) is trending as traders discuss a potential short squeeze, fueled by news surrounding quantum computing and Bitcoin investments. The stock's volatility and past runs are driving speculation, with some comparing it to the $GME squeeze. Community members are actively debating price targets and whether $HOLO will experience another multi-day run.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI ($SOUN) is trending as investors discuss its recent partnership with Red Lobster to implement AI-powered phone ordering across all locations, with many viewing this as a catalyst for further expansion and a signal of growing momentum. Community members are highlighting the potential for increased clientele from well-known chains and the positive implications of replacing human jobs across various sectors with AI agents. Bullish sentiment is fueled by the anticipation of a short squeeze and a potential surge towards higher price targets, with some drawing parallels to the broader AI sector and SoundHound's competitive positioning.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is trending following the announcement of a potential $245 million sole-source contract with the U.S. Defense Logistics Agency, which is driving significant excitement among investors who have been following the company for years. The community is discussing the potential for expansion and acquisitions, with some speculating that UAMY could be the next major player in the antimony market. Some analysts have also set price targets significantly higher than its current trading price.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid discussions about the FTC trial regarding Prime subscriptions and its potential impact. Community sentiment is mixed, with some expressing frustration over the stock's performance while others see a buying opportunity, particularly with upcoming events. News of Amazon closing UK stores and broader logistics partnerships are also circulating, contributing to the stock's current buzz.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending as traders anticipate a potential short squeeze and speculate about upcoming news or contract announcements. Community members are actively discussing resistance levels and potential price targets, drawing comparisons to Palantir ($PLTR) and highlighting the company's position in the AI and defense sectors. Bullish sentiment is fueled by the stock's recent upward momentum and BlackRock's increased stake.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending as community members discuss its potential following news of advancements in quantum internet technology, which could lead to new government contracts and increased investment. Bullish sentiment is fueled by short squeeze potential and comparisons to other high-growth tech companies, while some traders express caution due to valuation concerns and potential for a pullback. The stock's momentum and potential impact on AI are key points of discussion.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining ($CIFR) is trending as investors discuss its potential in the AI data center space, drawing comparisons to peers like $IREN and $WULF. Community chatter highlights anticipation for a potential hyperscaler deal and upcoming earnings, with some eyeing price targets. Bullish sentiment suggests a pivot towards AI and HPC is fueling interest in the stock.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending due to reports of potential fines from the FAA related to safety violations, sparking concerns about ongoing regulatory scrutiny and its impact on the 737 MAX program. The community is also closely watching union negotiations, as the latest contract offer was rejected, prolonging the strike. Despite some positive delivery news, broader concerns around production quality, CEO commentary, and the overall financial health of the company are fueling negative sentiment.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance (BETR) is trending due to activist investor Eric Jackson's bullish stance, comparing it to the "Shopify of mortgages" and predicting substantial gains. The community is actively debating the potential synergies with Opendoor ($OPEN) and whether the recent surge is sustainable or a shorting opportunity, while also questioning the company's fundamentals and long-term prospects within the rate-sensitive mortgage sector.

Super League Enterprise, Inc. creates innovative and immersive entertainment experiences, platform and audience monetization and dynamic content feeding channels across the world’s top gaming platforms. Fueled by an insatiable desire to stay on the forefront of this ever-evolving meta landscape, Super League pioneer's proprietary digital solutions provide unparalleled access to the global gaming audience. It also creates vibrant in-game communities through the development of innovative experiences and custom content, delivering powerful opportunities for brands and advertisers to achieve impactful insights, and marketing outcomes with audiences of all ages. The company was founded by John C. Miller, David Steigelfest, and Brett Morris on October 1, 2014 and is headquartered in Santa Monica, CA.

Super League Enterprise Inc

Super League Entertainment is trending due to a planned $10 million strategic investment from Evo Fund, sparking discussions about the company's crypto expansion plans and potential to meet Nasdaq requirements. Community members are actively trading the stock, speculating on potential breakouts and short squeezes, while also debating the long-term implications of the investment and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm 

VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, in combination with Tirzepatide, helped preserve lean mass during Tirzepatide-induced weight loss in a mid-stage study.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-positive-phase-2-embraze-trial-results">trial</a> demonstrated that 30% of the total weight loss with Tirzepatide alone was due to lean mass loss. Tirzepatide is the active ingredient in Eli Lilly's weight loss therapy Zepbound.Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.Reduction in body weight, however, was marginally higher in patients who received Tirzepatide alone.No subjects experienced serious adverse events or discontinuations considered to be related to apitegromab treatment, and there were no deaths, the company added.Akshay Vaishnaw, President of R&amp;D, Scholar Rock, said that while therapies like Tirzepatide have been an effective innovation for people with obesity, they result in substantial loss of lean muscle mass for patients, leading to unwanted health risks.Vaishnaw added that the company is focused on preparing for the launch of Apitegromab and, following its potential approval for spinal muscular atrophy, looks forward to studying it in a range of neuromuscular diseases with high unmet needs.Approval for Apitegromab in spinal muscular atrophy is expected by late September.Scholar Rock is not alone in attempting to preserve lean mass during drug-induced weight loss. Earlier this month, Regeneron (REGN) said that a mid-stage trial demonstrated that approximately 35% of Semaglutide-induced weight loss was due to loss of lean mass. However, combining Semaglutide, the active ingredient in Novo Nordisk’s weight loss drug Wegovy, with Regeneron’s Trevogrumab with or without Garetosmab helped preserve lean mass while increasing loss of fat mass, the company said.On Stocktwits, retail sentiment around Scholar Rock jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_1_49_41_PM_png_73aabfb93c.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:50 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, noted that the lack of increased weight loss with the combination compared to Tirzepatide alone is bearish.<stembedurl>https://stocktwits.com/BioLong123/message/618251994</stembedurl><a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> is down by 18% this year but up by over 320% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/coinbase-circle-pop-as-stablecoin-legislation-clears-senate/chlsfGnRR2K">Coinbase, Circle Pop As Stablecoin Legislation Clears Senate – But These Two Stocks Took A Hit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Equity

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.



Shares of Akero Therapeutics, Inc. (AKRO) jumped 3% on Friday afternoon after Jefferies said the company has a “promising” takeover potential.Jefferies thinks big pharma companies are "still on the hunt" for deals as Pfizer (PFE), Biogen (BIIB), Merck (MRK), Eli Lilly (LLY), Gilead (GILD), and others have publicly discussed active business development to "fill voids."Jefferies named South San Francisco-based Akero among the names it believes hold promise, alongside Scholar Rock (SRRK).The firm noted that Akero has potential sales of $2 billion to $3 billion and "clean and strong" Phase II data of its lead product candidate, Efruxifermin, in patients with non-alcoholic Steatohepatitis.As for Scholar Rock (SRRK), Jefferies deems it a promising target with likely approval for its investigational treatment Apitegromab in spinal muscular atrophy by late September.The company’s upcoming mid-stage trial data of Apitegromab in obesity "could be a clearing event" that could help simplify the stock's valuation, it added.On Stocktwits, retail sentiment around Akero stayed within ‘bearish’ territory over the past 24 hours, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:625/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_36_24_PM_png_6b185bcea0.webp" alt="AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="625" height="66"><figcaption>AKRO's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure>According to data from Koyfin, all 11 analysts covering AKRO rate it a ‘Buy’ or higher. The stock has an average price target of $76.30.Meanwhile, retail sentiment around SRRK stayed ‘bearish’ over the last 24 hours while message volume took a dip from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:633/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_1_37_19_PM_png_cb246dfd4a.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="633" height="65"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:35 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure> All of the 10 analysts covering SRRK also rate it ‘Buy’ or higher, with an average price target of $49.67.While <a href="https://stocktwits.com/symbol/AKRO">AKRO</a> has nearly doubled its value this year, <a href="https://stocktwits.com/symbol/SRRK">SRRK</a> is down by over 25%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/merck-gets-fda-approval-for-keytruda-in-more-head-and-neck-cancer-patients/chliQJzRRbZ">Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mergers and Acquisitions message in neon lights. (Image Courtesy: Getty Images)

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased

Jefferies thinks big pharma companies are "still on the hunt" for deals. 

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases...

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the Company), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious...

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock Holding Corp

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

SRRK
Scholar Rock Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SRRK News

SRRK Scholar Rock Holding Corp